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Little is known about referrals from primary care providers (PCPs) for
suspected hematologic malignancies, including their clinical triggers
and frequency. A random sample of 190 Massachusetts PCPs were
presented with a vignette concerning a patient with a new finding of
moderate anemia, asked how they would respond, and then asked
what they would do if the patient returned with persistent anemia plus
one additional sign or symptom. We also asked about referral behav-
iors for suspected hematologic malignancies during the prior year. A
total of 134 (70.5%) PCPs responded. At first anemia presentation,
only 3.8% reported referring to hematology. The development of a sec-
ond sign or symptom yielded higher referral rates: pancytopenia 5
88.7%, leukopenia 5 63.9%, thrombocytopenia 5 63.9%, lymphadenop-
athy 5 42.9%, leukocytosis 5 37.6%, night sweats 5 25.6%, and weight
loss 5 23.3%. The median yearly number (interquartile range) of
patients PCPs reported suspecting of having hematologic malignancy
was 5 (3, 10), and the median formally referred was 5 (3, 10). We con-
clude that anemia plus signs and symptoms suggestive of myelodys-
plasia or leukemia (compared with those suggestive of lymphoma) are
more likely to prompt hematology referral. In addition, given their rar-
ity, the number of yearly referrals suggests a satisfactory level of PCP
surveillance.
The primary care physician (PCP) is frequently the first point of contact for
patients with cancer and thus serves a vital role in detecting symptoms, mak-
ing diagnoses, and facilitating initiation of treatment. There is an extensive lit-
erature regarding PCP referrals for solid tumors, especially for malignancies
such as breast and gastrointestinal cancer where there are abundant evi-
dence-based screening guidelines [1–4]. In contrast, little is known about
referrals for suspected hematologic malignancies [5], such as the frequency
of such referrals, their clinical triggers, the factors that influence the choice of
hematologist, and the quality of information exchanged. In the case of chronic
hematologic malignances such as myelodysplasia, multiple myeloma, follicu-
lar lymphoma, and chronic lymphocytic leukemia, PCPs may have a lack of
knowledge of so-called ‘‘alarm symptoms,’’ and sparse experience with rele-
vant diagnostic workups [6,7]. As even chronic blood cancers can be lethal
and are increasingly treatable [8–11], prompt and efficient referral by PCPs
for suspected hematologic malignancies is likely to improve care.
We aimed to survey a broad sample of PCPs as to their referral practi-
ces for suspected hematologic malignancies. We first sought to evaluate
their approach to anemia (both singly and in combination with subsequent
clinical findings), as anemia is a common first presenting sign for hemato-
logic cancers. We then aimed to characterize how often PCPs suspect
hematologic malignancy, the frequency and type of resulting consultation,
the factors that affect their choice of hematologist, and the quality of infor-
mation exchanged upon referral. Finally, we were also interested in how
PCPs perceive their own ability to diagnose and treat these disorders, how
often referrals have been completed when patients are seen in follow-up,
and ultimately, how PCPs view the quality of the referral system within
which they operate.
A total of 134 (70.5%) of 190 eligible Massachusetts PCPs completed sur-
veys; 37 opted out either by postcard or when contacted by telephone, and
the remaining 19 never responded. Most respondents were male (58.7%)
and identified as internists (67.7%). PCPs were approximately evenly-distrib-
uted with respect to academic affiliation, with 21.1% reporting no affiliation
with an academic center and 17.3% reporting being full-time faculty. The
median reported patient panel size during the prior 12 months was 1,800
patients, and the median percentage of patients  65 years was 30.0%
(Supporting Information Table 1).
Clinical actions for isolated anemia are shown in Table I; clinical actions
for persistent anemia and one additional sign or symptom are shown in
Table II. Of note, among patients most likely to be referred to a hematologist
(those with pancytopenia, thrombocytopenia, or leukopenia), PCPs reported
recommending low levels of 2-week follow-up in addition to the referral
(10.6%, 16.7%, and 15.6%).
TABLE I. PCPs’ First Reported Clinical Action when Patient Presents with
New-Onset Anemia (Hg 5 80% of Normal)a
PCP action % Reporting
Iron studies 93.2
Differential 85.7
B12/folate 85.0
Stool guaiac 69.2
Reticulocyte count 66.2
2-week follow-up 30.8
Colonoscopy 26.3
SPEP 17.3
Depends on age 12.0
EGD 8.3
Refer to hematologist 3.8
Obtain imaging 1.5
a
Respondents could choose more than one action.
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Among all respondents, the median number (IQR) of patients in the prior
12 months suspected of having a hematologic malignancy was 5 (3, 10); of
those suspected patients, the number formally referred to a specialist was 5
(3, 10), and the median number to receive curbside consultation was 0 (0,
0). PCP characteristics associated with higher levels of suspicion of hemato-
logic malignancies are reported in Table III. Accounting for panel size, PCPs
with stronger academic affiliation reported being more suspicious of hemato-
logic malignancy than other physicians, while PCPs with a higher proportion
of patients in managed care as well as those who were more recent gradu-
ates reported suspecting fewer patients of having hematologic malignancy.
Table III also details PCP characteristics associated with curbside consulta-
tion and formal referrals, adjusting for the number of patients suspected to
have hematologic malignancy.
When considering to whom to refer, respondents rated specialist reputation
(96.2%) as most important, while the possibility of losing a referred patient to a
specialist was rated as least important (15.8%; Supporting Information Table
2). Among respondents who did not report ‘‘always or usually’’ writing a formal
letter and/or an email (49.6%), 62.5% reported ‘‘always or usually’’ giving a
patient test results to take to the specialist meeting (Supporting Information
Table 3). Thus, 18.9% of all patients were reportedly sent to hematologic spe-
cialists with no documentation (email, letter, or test results given to patient).
Finally, 38.4% of respondents reported that patients have not seen the special-
ist ‘‘always, usually or sometimes’’ at the time of PCP follow-up, although only
2.3% reported that this ‘‘always or usually’’ occurs.
We found that PCPs were highly suspicious of hematologic malignancies,
reporting both suspecting and referring a median number of five patients per
year out of a median annual patient panel size of 1800. This rate of suspi-
cion and referral (278 per 100,000) greatly exceeds the national incidence
rates of malignancies such as non-Hodgkin’s lymphoma (19.5 per
100,000)[12] and myelodysplasia (3.5 per 100,000)[13], and even that for all
of the hematologic malignancies combined. Our data suggest that even in
the absence of national screening guidelines, PCPs are performing an
acceptable job in terms of suspecting hematologic malignancy and referring
those patients to hematologists.
In our two-step anemia vignette, signs and symptoms suggesting myelo-
dysplasia or leukemia most often prompted early referral, while those sug-
gesting lymphoma were generally followed by imaging. This seems clini-
cally reasonable, but still may result in delay of diagnosis and treatment by
trained hematologic specialists. Interestingly, we found that an insistent
family member could influence hematology referral for persistent anemia
more so than night sweats, leukocytosis, or weight loss. We also found
that several lower-cost and effective laboratory tests (e.g., reticulocyte
count) were relatively underutilized, while over 25% reported obtaining
colonoscopy as a first step. Taken together, these findings suggest that uti-
lization of diagnostic anemia protocols may be a way to both improve care
and decrease costs.
We found that recent residency graduates suspected fewer hematologic
malignancies than other physicians, an observation that may be explained
by their lack of clinical experience. Moreover, when younger PCPs did sus-
pect hematologic malignancy, they more often formally referred patients and
less often sought curbside consultation. We also found that PCPs with a
high number of older adults in their practice suspected fewer hematologic
malignancies. This was surprising given that hematologic malignancies are
significantly more prevalent in older adults and the gap between so-called
‘‘alarm symptoms’’ and actual cases of malignancy is felt to be smaller in
the elderly [6]. This may be explained by the recent finding that even classic
signs and symptoms of hematologic malignancy (such as anemia and back
pain in multiple myeloma) can be effectively hidden by significant comorbid-
ity [14], which itself is more likely in older adults.
Our respondents reported that approximately one in five hematology
referrals are made without any formal documented information exchange.
Although our survey did not include every potential way for a PCP to con-
tact a specialist (e.g., phone or shared medical record), these results
suggest that there may be a gap in the flow of information between PCPs
and hematology specialists. A recent national survey of 4720 PCPs and
specialists found that while 69.3% of PCPs reported ‘‘always’’ or ‘‘most of
the time’’ sending notification of the reason for referral, only 34.8% of
specialists said they ‘‘always’’ or ‘‘most of the time’’ receive such informa-
tion [15]. The lack of formal referral letters, emails, or even conveyance
of test results may result in the specialist failing to obtain essential medi-
cal history [16] and may also foster replication of costly tests and proce-
dures [17]. The former issue is especially important in hematologic oncol-
ogy, as changes in blood counts over time—rather than absolute values
at presentation—are often key to understanding potential progression of
disease.
We recognize limitations to our work. First, our finding that the referral
system for hematologic malignancies functions relatively well may not be
completely generalizable to other states, especially ones that lack a large
metropolitan region such as Boston (which contains several tertiary-care
hospitals). Second, despite our excellent response rate (70.5%) for a physi-
cian survey, [18] our overall sample size was limited, which reduced our
power to assess some associations in our analyses. Third, our work may
have been affected by participation bias, as the PCPs who answered our
survey may have also been those physicians most likely to actively suspect
hematologic malignancies. Although participation bias is less of a concern
when obtaining a high response rate such as ours, as with any cross-sec-
tional survey, our study was also subject to recall bias (e.g., selective mem-
TABLE II. PCPs’ Reported Clinical Actions When Patient Presents with
Persistent Anemia (Hg 5 80% of Normal) and One Additional Sign
or Symptoma
Sign/Symptomb Imaging (%)
Hematologist
referral (%)
2-Week
follow-up (%)
Fever 46.6 8.3 58.7
Leukocytosis 33.1 37.6 51.1
Leukopenia 15.8 63.9 28.6
Lymphadenopathy 67.7 42.9 28.6
Night Sweats 69.2 25.6 37.6
Pancytopenia 9.8 88.7 12.8
Thrombocytopenia 15.0 63.9 32.3
Thrombocytosis 15.0 42.9 48.1
Weight loss 54.1 23.3 43.6
Insistent family 21.1 39.9 57.9
Patient feels unwell 32.3 6.8 77.4
a
Note: Respondents could choose more than one action.
b
All row differences were significant at P  0.01.
TABLE III. Associations of PCP Characteristics with Number of Patients Suspected of Having Hematologic Malignancy,
Curbside Consultation Requested, and Formal Consultation Requesteda
PCP characteristics
Adjusted odds ratio for
number of patients for
whom hematologic
malignancy suspectedb
Adjusted odds ratio for
number of patients
for whom curbside requestedc
Adjusted odds ratio for number of
patients for whom formal
referral requestedd
Stronger academic affiliation (3 vs. <3) 1.91 [1.74–2.10] 1.04 [0.66–1.52] 0.35 [0.25–0.50]
High number elderly patients (top quartile vs. lower quartiles) 0.95 [0.84–1.07] 1.12 [0.70–1.80] 0.28 [0.18–0.44]
High number managed care patients (above median vs. below) 0.46 [0.41–0.51] 3.71 [2.37–5.81] 0.33 [0.22–0.50]
More recent residency completion (1996 or later vs. before 1996) 0.73 [0.66–0.81] 0.34 [0.22–0.52] 7.68 [5.03–11.73]
Primarily internal medicine vs. other 0.55 [0.50–0.61] 0.66 [0.41–1.05] 0.29 [0.21–0.42]
a
From binomial logistic regression, adjusting for all other variables in the table as well as gender and race/ethnicity (white vs. other).
a
Odds ratio for (# Suspected)/(Total # Patients in Panel) with [95% Confidence Interval].
c
Odds ratio for (# Curbside/# Suspected) with [95% Confidence Interval].
dOdds ratio for (# Formal/# Suspected) with [95% Confidence Interval].
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ory of referral behaviors), information bias (e.g., knowledge gap of patient
panel demographics, digit preference bias), and social desirability bias (e.g.,
disinclination to report aberrant referral behaviors).
In summary, we found that anemia plus signs and symptoms suggesting
of myelodysplasia or leukemia (compared with those suggestive of lym-
phoma) are more likely to prompt early hematology referral, and that overall,
there was an adequate level of suspicion for hematologic malignancy among
PCPs. We also found a high level of formal referrals rather than curbside
consultation, and PCPs reported that most referrals were completed upon
follow-up. We thus conclude that despite the absence of specific guidelines
for screening and surveillance, the overall referral system for suspected
hematologic malignancies functions relatively well.
Methods
Details of our survey method have been described previously [19]. Briefly,
the names of all Massachusetts PCPs were obtained from the American
Medical Association in March of 2010; 375 of these were randomly selected
for inclusion in the survey. We then searched the Massachusetts Board of
Registration in Medicine online directory to verify that the physicians (1)
were currently in practice in Massachusetts; (2) graduated from medical
school in 2005 or earlier; (3) had a listed specialty or were board-certified in
internal medicine, general medicine, family medicine or geriatrics; and (4)
had no nonprimary care subspecialty listed. The final precontact eligible
sample consisted of 250 physicians. Of these, 60 reported upon contact that
they did not engage in primary care and were reclassified as ineligible. The
final eligible sample thus included 190 PCPs.
Survey questions were devised utilizing established standards for survey
development [20,21]. Pilot testing and cognitive debriefing with three PCPs
and two hematologists allowed for iterative revision in addition to assess-
ment of face validity, content validity, and response burden. The 34-item
questionnaire included questions about PCPs ‘‘Professional Background’’
and sections entitled ‘‘Signs and Symptoms,’’ ‘‘Flow of Referral Information,’’
‘‘Deciding to Refer and Choosing a Specialist,’’ and ‘‘Final Questions About
You’’ (sociodemographic questions about the respondent, adapted from the
Consumer Assessment of Healthcare Providers and Systems (CAHPS) 3.0
Survey ‘‘demographic’’ domain) [22]. The study was approved by the Dana-
Farber/Harvard Cancer Center Office for Human Research Studies.
Recruitment was by FedEx1 courier services, with follow-up telephone
contact; all PCPs who completed the survey received a $100 VISA gift card.
For the vignette questions, initial anemia workup actions were analyzed
descriptively; significant differences in the second stage (anemia plus one
additional sign or symptom) were identified using Wald chi-square statistics
obtained from logistic regression models. We next assessed the number of
suspected hematologic malignancies, formal referrals, and curbside consul-
tations in the entire cohort reported for the prior year, calculating the median
number and interquartile range (IQR) for each variable. We did not adjust
for panel size, as we were aiming to report median suspicion and referral
burden among the total responding physician population for each item, a
number we felt was most important from a resource utilization perspective.
Next, using multivariable binomial regression analysis, we assessed PCP
characteristics associated with higher numbers of suspected hematologic
malignancies, this time taking into account the size of each PCP’s patient panel.
Finally, we analyzed responses to questions about choice of specialist and flow
of referral information. Likert scale responses were dichotomized, and bivariate
associations of these answers with PCP variables were assessed utilizing Fish-
er’s exact test. Variables significant on univariate analysis (P < 0.05) were
entered into multivariable models using backwards elimination. Analyses were
conducted with the SAS statistical package (SAS 9.2, SAS Institute, Cary, NC).
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